US health regulators have granted [b]Novartis'[/b] meningitis B vaccine [b]Bexsero[/b] breakthrough therapy status. The company said it plans to file for US approval of Bexsero as early as the second quarter of this year. The vaccine already has approval in Europe, Canada and Australia and has been administered at several universities in the US to stop outbreaks of meningitis across campuses.
[link url=http://www.reuters.com/article/2014/04/07/us-novartis-usa-bexsero-idUSBREA3607V20140407] Reuters Health[/link]